Salute e Benessere
Continuity Biosciences Invests in PinPrint, Inc., Expanding into Aesthetic and Cosmetic Drug Delivery
PinPrint's lead innovation is a next-generation microneedle patch designed to deliver vaccines and active agents intradermally, replacing the need for traditional injections. said Dr. DeSimone.
This strategic investment aligns with Continuity's mission to advance targeted delivery technologies. The company is currently developing implanted nanofluidic platforms through its work with the Grattoni Lab at Houston Methodist Hospital, with capabilities for extended, zero-order release. said Ramakrishna Venugopalan, PhD, Co-Founder and CEO of Continuity Biosciences.
As part of the transaction, Dr. Venugopalan will join PinPrint's Board of Directors. said Renee Ryan, MBA, Co-Founder and CEO of PinPrint, Inc. "
About Continuity Biosciences
Continuity Biosciences, LLC develops advanced drug delivery technologies for chronic and complex diseases. Headquartered in
Bradenton, FL , with operations in
Houston, TX , the company is committed to enhancing precision and effectiveness in therapeutic delivery.
www.continuitybiosciences.com
About PinPrint, Inc.
PinPrint, Inc. is revolutionizing drug and vaccine delivery through precision 3D-printed microneedle platforms. By transforming the way medicines are administered, PinPrint aims to improve outcomes and patient comfort across therapeutic and aesthetic applications.
Logo - https://mma.prnewswire.com/media/2555793/Continuity_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/continuity-biosciences-invests-in-pinprint-inc-expanding-into-aesthetic-and-cosmetic-drug-delivery-302440373.html